Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer - PubMed (original) (raw)

. 2009 Sep 15;69(18):7466-72.

doi: 10.1158/0008-5472.CAN-08-4385. Epub 2009 Sep 8.

Joe Zhu, Clay L Efferson, Chris Ware, Jennifer Tammam, Minilik Angagaw, Jason Laskey, Kimberly A Bettano, Shailaja Kasibhatla, John F Reilly, Cyrille Sur, Pradip K Majumder

Affiliations

• PMID: 19738074
• DOI: 10.1158/0008-5472.CAN-08-4385

Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer

Weisheng Zhang et al. Cancer Res. 2009.

Abstract

Androgen receptors have been shown to play a critical role in prostate cancer. We used ultrasound imaging techniques to track tumor response to antiandrogen and rapamycin treatment in a prostate-specific Pten-deleted mouse model of cancer. Depletion of androgens by either surgical or chemical castration significantly inhibited tumor growth progression without altering the activation of Akt and mammalian target of rapamycin (mTOR). We also showed for the first time that targeting mTOR along with antiandrogen treatment exhibited additive antitumor effects in vivo when compared with single agents. Our preclinical data suggest that combination of antiandrogens with mTOR inhibitors might be more effective in treating androgen-dependent prostate cancer patients.

PubMed Disclaimer

Similar articles

• Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
  Wu L, Birle DC, Tannock IF. Wu L, et al. Cancer Res. 2005 Apr 1;65(7):2825-31. doi: 10.1158/0008-5472.CAN-04-3137. Cancer Res. 2005. PMID: 15805283
• Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
  Narayanan NK, Nargi D, Randolph C, Narayanan BA. Narayanan NK, et al. Int J Cancer. 2009 Jul 1;125(1):1-8. doi: 10.1002/ijc.24336. Int J Cancer. 2009. PMID: 19326431
• Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
  Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Grünwald V, et al. Cancer Res. 2002 Nov 1;62(21):6141-5. Cancer Res. 2002. PMID: 12414639
• Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
  Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Squillace RM, et al. Int J Oncol. 2012 Aug;41(2):425-32. doi: 10.3892/ijo.2012.1487. Epub 2012 May 18. Int J Oncol. 2012. PMID: 22614157 Free PMC article.
• PTEN-mediated pathways and their association with treatment-resistant prostate cancer.
  Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA. Uzoh CC, et al. BJU Int. 2009 Aug;104(4):556-61. doi: 10.1111/j.1464-410X.2009.08411.x. Epub 2009 Feb 13. BJU Int. 2009. PMID: 19220271 Review. No abstract available.

Cited by

• Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.
  Zhang R, Singh S, Pan C, Xu B, Kindblom J, Eng KH, Krolewski JJ, Nastiuk KL. Zhang R, et al. Am J Clin Exp Urol. 2023 Feb 25;11(1):12-26. eCollection 2023. Am J Clin Exp Urol. 2023. PMID: 36923722 Free PMC article.
• Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
  Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Carver BS, et al. Cancer Cell. 2011 May 17;19(5):575-86. doi: 10.1016/j.ccr.2011.04.008. Cancer Cell. 2011. PMID: 21575859 Free PMC article.
• Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia.
  Pan C, Jaiswal Agrawal N, Zulia Y, Singh S, Sha K, Mohler JL, Eng KH, Chakkalakal JV, Krolewski JJ, Nastiuk KL. Pan C, et al. JCI Insight. 2020 Mar 26;5(6):e127018. doi: 10.1172/jci.insight.127018. JCI Insight. 2020. PMID: 32078585 Free PMC article.
• Targeting treatment options for castration-resistant prostate cancer.
  Miller DR, Ingersoll MA, Teply BA, Lin MF. Miller DR, et al. Am J Clin Exp Urol. 2021 Feb 15;9(1):101-120. eCollection 2021. Am J Clin Exp Urol. 2021. PMID: 33816699 Free PMC article. Review.
• Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.
  Chetram MA, Odero-Marah V, Hinton CV. Chetram MA, et al. Mol Cancer Res. 2011 Jan;9(1):90-102. doi: 10.1158/1541-7786.MCR-10-0235. Epub 2010 Nov 12. Mol Cancer Res. 2011. PMID: 21076047 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal
  • SciCrunch